Chinese exec fined for insider trading

Share this:

The board chairman of Chinese pharmaceutical company Hunan Fangsheng Pharmaceutical Co., Ltd has been fined 600,000 yuan. (~€77,000/~$91,000) in an insider trading case. Chinese officials started investigating the company in June 2019 following a rise in Fangshen shares the previous April when the company announced it had signed a cooperation agreement with the government of Huize County, Yunnan, to develop hemp farming and processing operations. The company later admitted in a subsequent announcement that the project was still in the planning phase and faced uncertainty, causing Fangshen’s stock to fall sharply. 

Recent Posts

Proposed ban on smokable hemp products under fire in France

Draft regulations for CBD in France would ban the sale of smokable hemp products and…

June 15, 2021

Hemp operators in Portugal frustrated by questionable rules

Portuguese hemp stakeholders say rules in a new law covering medical cannabis and hemp put…

June 14, 2021

1996: Hemp shaking its seedy past

Celebrating Hemp History Month – [Santa Rosa Press Democrat, Jan 29 1996] – It’s no…

June 14, 2021

Débora Paulino will head HempToday’s new Portuguese language edition

HempToday has launched a Portuguese language news service covering industrial hemp, the fifth non-English iteration…

June 14, 2021

NFL will spend $1 million to study cannabinoids in pain management

The U.S. National Football League (NFL) said it will award $1 million in grants for…

June 11, 2021

Passage of law in Argentina could spark $500 million market

Regulated medical cannabis and hemp industries in Argentina could generate 10,000 new jobs, $500 million…

June 11, 2021